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Abstract: An automated docking procedure was applied to study the binding of a 
series of μ- and δ-selective ligands to ligand-specific μ- and δ-opioid receptor mo-
dels. Short-time molecular dynamic simulations were used to obtain ligand-specific 
μ- and δ-opioid receptors from arbitrarily chosen models of the active form of these 
receptors. The quality of receptor model depended on the molecular volume of the 
ligand in the receptor–ligand complex used in the molecular dynamic simulations. 
Within a series of ligands of similar size (volume), the results of ligand docking to 
the obtained ligand–specific receptor conformation were in agreement with point 
mutation studies. The correlation of the calculated and the experimentally deter-
mined binding energies was improved in relation to the initial receptor confor-
mation. 
Keywords: molecular modeling; opioid receptor; ligand–receptor interactions; dock-
ing simulation. 
INTRODUCTION 
Three types of opioid receptors: μ, δ and κ (or MOR, DOR and KOR, res-
pectively), are involved in pain regulation by inhibiting neuronal adenylyl cyc-
lase activity, but they also participate in the regulation of multiple other effec-
tors.1 There are also studies indicating that the δ-opioid receptor and/or its speci-
fic ligands are involved in cardioprotection.2 Based on the results of pharmaco-
logical investigations,3 opioid receptors have been subdivided into receptor sub-
types, but the molecular basis of these subtypes remains to be resolved. Both, 
MOR and DOR have been cloned.4–6 A hypothesis was made7 that selective 
ligands might bind the same receptor but at different binding sites. The ability of 
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the selective ligands to bind their respective binding site would depend on the 
conformational state of the opioid receptor.7,8 
The regions of MOR and DOR involved in ligand binding and mediation of 
receptor function have been identified: a) by the construction of chimeric recep-
tors containing sequences of MOR or DOR receptors,9–14 b) by site-directed 
mutagenesis of specific amino acid residues15–21 and c) by the construction of 
truncated mutant receptors.22–26 
In the case of DOR, it was found by point-mutation experiments21 that 
Asp95Asn mutation reduced the affinity of many DOR-selective peptidic and 
non-peptidic agonists for DOR. Studies5 on chimeric and site-mutagenized DOR 
established the importance of the third extracellular loop (EC3) arginine amino 
acids for the binding of peptidic ligands while non-peptidic ligands were unaf-
fected. Site-directed mutagenesis experiments showed16 that Asp128 contributes 
to the stabilization of the binding pocket. Mutations of amino acids Tyr129Phe, 
Trp274Ala and Tyr308Phe suggested that these aromatic residues might be a part 
of an opioid binding domain. Chimeric receptors and the alanine scan method 
were used11 to show that Leu295, Val296, Val297 and Ala298 of the EC3 loop 
are important for the binding of DOR-selective ligands. The amino acids Trp284 
(TM6) and Ser312 (TM7) are important but to a lesser degree. It was also found12 
that modifications of the second extracellular loop (EC2) had no effect on ligand 
binding. Other chimeric receptor studies13 demonstrated that the sixth transmem-
brane domain (TM6) and the third extracellular loop (EC3) are absolutely critical 
for δ-opioid receptor selectivity. Point mutations emphasized the importance of 
Leu300, Ala298, Ala299 amino acids, and the unimportance of Arg291 for ligand 
binding. Val281 had moderate effect on ligand binding.13 It was suggested18 that 
interactions [Asp128(TM3)–Tyr308 (TM7) and Tyr129 (TM3)–His278(TM6)] 
maintain the δ-receptor in an inactive conformation. Point-mutation experi-
ments19 confirmed that Trp284 (TM6) is important for the binding of ligands to 
the DOR, and that amino acids at the extracellular end of TM6 and TM7 are key 
residues for δ-ligand selectivity. Binding studies27 on a series of non-peptidic DOR 
ligands revealed that the binding site of these ligands is between TM5 and TM7 
of the DOR. The binding pocket for most DOR-selective ligands is located close 
to the EC3 loop and between the transmembrane helices TM3, TM6 and TM7.  
It was found by chimeric receptor studies9 that the major determinant for the 
binding of MOR-selective alkaloids exists in the region spanning the transmem-
brane segments TM5 to TM7 of the MOR. Segments TM6 and TM7, as well as 
the third extra-cellular (E3) loop of the μ-receptor, were important28 for the bind-
ing of agonists, such as morphine and fentanyl analogs, while the first extra-cel-
lular loop (E1) was not important for MOR-selective non-peptide ligands. Site 
directed mutagenesis studies15 indicated that Asp147 is the primary binding site 
in the MOR, as the counter ion for the protonated nitrogen of opioid ligands. The 
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importance of charged residues in TM2 (Asp 114), TM3 (Asp147) and TM6 
(His297) was evidenced,15 as well as the modest involvement of N- and C-ter-
minal domains in the ligand–receptor interactions. Site directed mutagenesis stu-
dies29–31 established the importance of the TM7 residues Cys321, Tyr326, 
Trp318 and His319 and the TM3 residue Tyr148 for the activation of MOP. It 
was also established by mutation experiments,32 that Asn230 of TM5 is involved 
in the binding of morphine.  
Some experiments33–36 suggested that important conformational changes in 
the receptor accompany ligand binding. Receptor states were discovered that can 
be activated without the effects of an agonist,37 shifting thus the understanding of 
receptor activation from a model of inactive and active conformations of a recep-
tor38 to theories of multiple signaling states whereby each agonist could import 
its own unique active conformation.39 
In this work, molecular dynamics were used to model ligand–specific re-
ceptor conformation from an arbitrary model of an active receptor. This ligand–
specific receptor conformation is expected to provide more realistic geometry of 
a receptor–ligand complex obtained by ligand docking, and to give a better corre-
lation between the calculated and experimentally determined binding energies 
within a series of closely related ligands. Molecular volume was the molecular 
descriptor which defined the closely related group of ligands.  
COMPUTATIONAL METHODS 
All computations were realized on an Intel(R) Core(TM)2 Quad CPU Q9650 at 3.00 
GHz or Silicon Graphics® Octane2 workstation. The initial active forms of the MOR and 
DOR models were obtained from Prof. H. I. Mosberg. The receptor models were based on the 
structure of the β2-adrenergic receptor (PDB code 2rh1) and were modeled in a receptor–
ligand complex with cyclic pentapeptide agonist ligands.40 The series of agonists (Tables I, II 
and III) were at first docked to the obtained original models of the active forms of the MOR or 
DOR. The receptor models were initially treated as rigid. In the second docking experiment, 
the flexibility of the binding pocket amino acids was taken into account. The automated fle-
xible ligand docking was performed by the Auto Docking program.41 
TABLE I. Compounds 1–11, ligands of the MOR 
Structure Compound  X  Y 
 
1 
2 
3 
C=O 
CH–OH 
C=O 
H 
H 
H 
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TABLE I. Continued 
Structure Compound  X  Y 
 
4  CH–OH H 
 
5 
6 
7 
8 
C=O 
C=O 
CH OH 
CH–OH 
OH 
H 
OH 
OH 
 
9 
10 
C=O 
CH–OH 
 
H 
H 
 
11  –C⋅⋅⋅OMe  – 
TABLE II. Morphine 3-esters, ligands of the MOR 
3
6
O
N
O R
O H
Compound R  Name 
4  H–  Morphine 
12  O 3-Benzoylmorphine 
13  O
Cl
3-(2-Chlorbenzoyl)-morphine 
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TABLE II. Continued 
Compound R  Name 
14 
O
Cl
Cl 3-(2,6-Chlorbenzoyl)-morphine 
15  O
Me
3-(2-Methylbenzoyl)-morphine 
16 
O
Me
Me 3-(2,6-Dimethylbenzoyl)-morphine 
17 
O
OMe
OMe
3-(2,6-Dimethoxybenzoyl)-morphine 
18  O 3-(2-Phenylbenzoyl)-morphine 
19  O 3-(α-Methylcinnamoyl)-morphine 
20  O 3-Pivaloylmorphine 
21 
O
3-(2,2-Diphenylpropionyl)-morphine 
In the subsequent docking experiments, the receptor models were optimized as follows. 
The selected ligands were manually docked to the original (obtained) receptor models using 
Accelrys Discovery Studio® (DS 2.5.5) visualizer. The orientation of the ligand inside the 
binding pocket was such as to: 1) provide interactions between the protonated nitrogen of the 
ligand and the important receptor residues (Asp 147 of TM3) in the MOR, or the corres-
ponding Asp128 in the DOR; 2) form a hydrogen bond between the OH group of the ligand 
and the His297 residue of TM6 in the MOR (or His 278 in the DOR) and 3) provide close 
interactions with Trp318 of TM7 in the MOR (or Leu300 in the DOR). The resulting complex 
structure was refined by molecular mechanics with a conjugated gradient algorithm in vacuum 
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to a RMS gradient below 0.4 kJ mol-1 nm-1, using CHARMm force field42 with Momany– 
–Rone charges.43 A short molecular dynamics simulation (5 ps) with 0.1 fs time steps at 300 
K was then applied. The lowest energy structure of the complex was selected and re-opti-
mized providing a ligand–specific receptor conformation. Docking with Auto Dock Vina was 
repeated using the ligand–specific receptor conformation as a rigid target. Calculated values 
TABLE III. Compounds 22–28, ligands of the DOR 
Compound name  Structure  Number 
SNC80  22 
SNC67  23 
BW373U86  24 
SIOM  25 
TAN-67  26 
SB219825  27 
SB206848  28 
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of the ligand binding energies were collected, and the structures of the resultant molecular 
complexes were analyzed. 
The initial ligand geometries, with protonated ring nitrogen,44 were built by application 
of HyperChem program45 and subsequently optimized by the semi-empirical PM3 method of 
the same program. The protein receptor and the ligands were prepared with MGL tools.46 A 
30×30×30 grid was applied, with the grid center positioned between Asp147 and His297 in 
the MOR (Asp128 and His278 in the DOR). The docking process was performed with 
exhaustiveness equal to 100. The resultant ligand orientations and conformations were scored 
based on binding energies (the cut-off value for the energies was 8.4 kJ mol-1), and by the 
formation of the salt bridge (shorter than 0.25 nm). The lowest binding energy conformations 
were further evaluated based on their distances to the important amino acids. The confor-
mation with the lowest binding energy, with a salt bridge shorter than 0.25 nm and with ma-
ximum number of close contacts to the important amino acids is referred to as the preferred 
conformation. 
RESULTS AND DISCUSSION 
Automated docking of compounds 1–21 to the original MOR model,40 and 
compounds 22–28 to the original DOR model40 resulted in a similar docking 
pattern. The ligands 1–11 in the MOR, in the best orientation for possible salt 
bridge formation with Asp147, are presented in Fig. 1. However, all the ligands 
are located in the wide cavity near the extracellular ends of the transmembrane 
helices TM3, TM6 and TM7. The distance between Asp147 (Asp128 in the DOR) 
and the protonated nitrogen of the ligand (O–⋅⋅⋅H–N+) was at least 0.6 nm, Fig. 1. 
Therefore, the key interaction for ligand binding and activation, which is be-
 
Fig. 1. Typical positions of the compounds 1–11 in the binding pocket of the initial MOR. 
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lieved to be the salt bridge formation, was not predicted by the model. The same 
was true for MOR ligands 12–21 and DOR ligands 22–28. The area in the ori-
ginal receptors, around Asp147 (Asp128 in the DOR) was too narrow to accom-
modate even small ligands and to allow the formation of the salt bridge. The use 
of receptors with flexible amino acids within the binding pocket did not improve 
the model. Moreover, the correlation of the calculated binding energies to the 
experimentally determined ones was poor, the correlation coefficient being –0.36 
for the compounds 1–11, Table IV. The experimentally determined and the cal-
culated binding energies had opposite trends, Fig. 2. 
This was expected since the original active receptors used in this work were 
modeled with voluminous molecules, i.e., naphthylalanine-substituted cyclic 
pentapeptide40 ligands. This is also in agreement with earlier results47 which 
suggested that ligands bind to their ligand–specific receptor conformations. 
TABLE IV. The studied MOR receptor agonist: molecular volume, experimentally deter-
mined Ki, binding energies, Eb(exp), and the binding energies calculated by Vina, Eb(calcd), 
for the initial MOR receptor, and the correlation coefficient between experimentally deter-
mined and calculated Eb values 
No. Ligand  name Molecular volume
nm
3 
Ki(exp) 
nM 
Eb(exp)
a
kJ mol
-1 
Eb(calcd) 
kJ mol
-1 
1  Hydromorphone 0.754 0.26
b –54.7 –34.3 
2  Dihydromorphine 0.758 0.39
b –53.7 –34.3 
3  Oxymorphone 0.765  0.36
c –53.9 –33.9 
4  Morphine 0.765  1.8
d –49.9  –33.5 
5  Oxycodone 0.811  16
e –44.5  –34.7 
6  Hydrocodone 0.801  19.8
c –44.0 –34.7 
7  β-Oxycodol 0.829  33.7
c –42.6 –33.1 
8  α-Oxycodol 0.814  187
c –38.4 –35.2 
9  Codeinone 0.790  459
f –36.2 –33.9 
10  Codeine 0.811  6300
f –29.7 –34.7 
11  Thebaine 0.847  7400
f –29.3 –34.7 
Correlation coefficient R (R
2) –  –  –0.36  (0.13) – 
aEb(exp) = 2.48 ln (10
-9Ki); 
bref. 48; 
cref. 49; 
dref. 50; 
eref. 51; 
fref. 52 
An effort was made to find the ligand specific receptor conformations of the 
MOR and DOR for ligands 1–28 by short molecular dynamics simulation of the 
complex obtained by manual docking of a specific ligand to the original receptor 
model.40 Since Auto Dock Vina does not take into account receptor flexibility, a 
unique receptor had to be modeled for a set of ligands of similar size. Therefore 
the MOR ligands were divided into two groups (group 1–11, Table I, and group 
12–21, Table II) based on their molecular volume, and the DOR ligands formed 
the third group, Table III. At least one representative molecule of small volume 
in each group was manually docked to the original receptor in such an orientation 
that a salt bridge was formed between the protonated nitrogen of the ligand and 
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Fig. 2. Trends in the binding energies, Eb, of ligands 1–11 with different receptor models. 
Original MOR – , MOR optimized with ligand 4 – , MOR optimized with ligand 
2 –  and MOR optimized with ligand 3 – . 
the Asp147 (Asp 128) of the receptor, and hydrogen bond formation was enabled 
between the phenolic hydroxyl group and the His297 (His278) of the receptor. 
The structure of a complex was optimized and subsequently submitted to the 
short molecular dynamics run. The lowest energy conformation of the complex 
found by molecular dynamics was isolated and re-optimized. The ligand was re-
moved and the optimized receptor model was used for docking. The collected 
binding energies Eb, and the resulting docking structures are presented in Table 
V, and Fig. 3, for the series 1–11. In this group of ligands, compounds 1–6 and 
10 were used for receptor optimization and docking in order to investigate the 
effect of ligand size on the quality of the receptor model. It can be seen in Table 
V and Fig. 2 that all ligands (1–4) with a small molecular volume improved the 
receptor model. This is illustrated by the increase of binding energy correlation 
coefficient from –0.36, for the initial MOR, to 0.83 for the receptor optimized 
with morphine (4) as the ligand. Only compound 1 insignificantly improved the 
correlation coefficient, just to a value of 0.22. The correlation coefficient for the 
larger molecules 5, 6 and 10 were either close to zero or had negative value. The 
best correlation of Eb was achieved with compounds 3 and 4 which, besides low 
molecular volume, had maximum number of hydrogen bond donors and accep-
tors. In addition, in the morphine (4) optimized receptor, the preferred ligand 
conformation was always the lowest energy conformation for ligands 1–10, Fig. 
3. Only thebaine (11) had no conformation with a salt bridge; it was in fact too 
big to enter the binding site created by the receptor optimization, which might be 
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the reason for its weak binding to the MOR, Ki = 7400. Therefore, although the 
original binding site at the top of the receptor was still present and accom-
modated the ligands, complex optimization provided the receptor model with a 
new binding site where the ligands bind with higher affinity. 
TABLE V. MOR receptor agonists: molecular volume, experimentally determined binding 
energies, Eb(exp), binding energies calculated by Vina, Eb(calcd), for the ligand specific MOR 
receptor 
No. Ligand  name 
Molecular 
volume 
nm
3 
Eb(exp)
a
kJ mol
-1
Eb(calcd) / kJ mol
-1 
Ligand used in complex optimization 
4 3 2 1 5  10  6 
1  Hydromorphone 0.754  –54.7  –38.5 –26.0 – –31.4 – –26.0  –36.8 
2  Dihydromorphine 0.758  –53.7 –35.6 –25.5 –31.4 –31.4 –35.2 –26.0  –33.9 
3  Oxymorphone 0.765 –53.9  –38.9 –27.6 –31.8 –33.9 –36.8 –26.8  –27.2 
4  Morphine 0.765  –49.9  –35.6 –25.5 –28.9 –33.5 –36.4 –26.4  –34.7 
5  Oxycodone 0.811  –44.5  –36.4 –24.7 –28.9 –33.5 – –28.0  –28.5 
6  Hydrocodone 0.801  –44.0  –35.6 – –27.2 –32.2 – –26.8  –37.3 
7  β-Oxycodol 0.829  –42.6  – – – – – –  –– 
8  α-Oxycodol 0.814  –38.4  –33.9 –23.9 –31.8 –32.2 –35.2 –27.6  –25.5 
9  Codeinone 0.790  –36.2  –35.2 –  –27.6   –38.5  –28.5   
10  Codeine 0.811  –29.7  –32.7 –  –26.0 –32.2 –36.0 –29.3  –36.4 
11  Thebaine 0.847  –29.3  –  –  –  –33.9 –40.2  –  – 
Correlation coefficient 
R (R
2) 
– –  0.83 
(0.69)
0.825 
(0.68)
0.65 
(0.43)
– – –  – 
aEb(exp) = 2.4775 ln (10
-9Ki); Ki from Table IV 
 
Fig. 3. Preferred conformations of compounds 1–10 in the binding pocket of the MOR 
optimized in the complex with morphine (4). 
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Based on these data, it was concluded that morphine 3-esters, Table II, are 
too large to use in the morphine-specific receptor model; hence, they must have 
their own, ligand–specific receptor model derived from a complex optimized 
with a representative ligand for the series 12–21. Docking of compounds 12–21 
to the original MOR resulted in complex structures with ligands positioned high 
in the receptor, between helices TM2–TM7, similar to compounds 1–11. None of 
the ligands had a salt bridge with Asp147. Ligand 15 was selected to be the 
representative ligand for receptor optimization because of its lowest molecular 
volume. The calculated and experimentally determined binding energies for com-
pounds 12–21 are reported in Table VI. The correlation of Eb(calcd) and Eb(exp) 
was poor, the correlation coefficient being close to zero. However, lower binding 
energies were obtained and the qualitative picture was improved, Fig. 4. The low 
energy conformations of the ligands have a salt bridge with Asp147 and close 
interactions with other important amino acids of the binding pocket, such as a 
hydrogen bond to Tyr148 and electrostatic interaction with His297. Only for 
compounds 14, 18 and 21, the experimentally determined Ki values of which 
were high and thus indicated weak binding, were conformations with a salt bridge 
not among the low energy ligand conformations. 
TABLE VI. MOR receptor ligands 12–21: molecular volumes, experimentally determined Ki, 
experimentally determined binding energies, Eb(exp), binding energies calculated by Vina, 
Eb(calcd), for the ligand specific MOR receptor (optimized with ligand 15) 
Ligand  Molecular 
volume, nm
3  Ki(exp)
a / nM Eb(exp)
b 
kJ mol
-1 
Eb(calcd) / kJ mol
-1 
Initial 
receptor 
Receptor optimized 
with ligand 15 
12  1.065 29  –43.1  –  –46.0 
13  1.106 160  –38.9  –  –45.2 
14  1.132 8200  –28.9  –  –42.3 
15  1.102 230  –37.7  –44.0  –47.3 
16  1.139 320  –36.8  –  –45.6 
17  1.209 360  –36.8  –  –40.6 
18  1.238 2600  –31.8  –  –45.6 
19  1.197 69  –41.0  –  –46.0 
20  1.038 52  –41.4  –  –38.1 
21  1.350 790  –34.7  –  –46.9 
Correlation 
coefficient R (R
2)
– –  –  –  0.02  (0.0004) 
aRef. 53; 
bEb(exp) = 2.4775 ln (10
-9Ki) 
The selected DOR agonists are presented in Table III and the resultant 
binding energies and molecular properties are reported in Table VII. Docking to 
the original DOR followed the same trends as the docking of the MOR ligands to 
the MOR. The ligands were positioned high in the receptor and none of the 
ligand conformations had a salt bridge with Asp 128. The correlation of the ex- 
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Fig. 4. Preferred conformations of compounds 13 and 21 in the 
binding pocket of the MOR optimized with ligand 15. 
TABLE VII. DOR receptor ligands 22–28: molecular volumes, experimentally determined Ki, 
experimentally determined binding energies, Eb(exp), binding energies calculated by Vina, 
Eb(calcd), for the initial receptor, and for the ligand specific DOR (optimized with ligand 26) 
Ligand  Molecular 
volume, nm
3  Ki(exp)
a / nM Eb(exp)
b 
kJ mol
-1 
Eb(calcd) / kJ mol
-1 
Initial 
receptor 
Receptor optimized 
with ligand 26 
22  1.377 0.818  –51.9  –33.1  –38.9 
23  1.378 218  –38.1  –35.6  –33.1 
24  1.319 0.086  –57.3  –34.3  –38.1 
25  1.155 4.1  –47.7  –49.4  –38.1 
26  1.000 0.649  –52.3  –36.8  –39.3 
27  1.213 0.6  –52.7  –34.3  –33.5 
28  1.096 1.7  –49.8  –39.3  –36.8 
Correlation 
coefficient R (R
2)
– –  –  0.23 
(0.053) 
0.56 0.32) 
aRef. 47 and references therein; 
bEb(exp) = 2.4775 ln (10
-9Ki) 
perimentally determined Eb values and the calculated ones was low, close to 
zero, Fig. 5. Ligand 26 with its low molecular volume was used for optimization 
of the receptor to its ligand specific conformation. The docking results with the 
optimized receptor are also reported in Table VII. The ligand preferred confor-
mations whose binding energies are reported, are the ones with low binding ener-
gies (within 8.4 kJ mol–1 above the global minimum), with a salt bridge shorter 
than 0.25 nm and the maximum number of interactions with other important 
amino acids of the binding pocket, Fig. 6. The trend of the binding energies for 
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the DOR ligands 22–28 showed improvement. While the correlation coefficient 
was close to zero, as in the case of the original receptor, it was corrected to 0.57 
(R2 = 0.33) for the optimized receptor, which confirms the necessity of using li-
gand specific receptor conformations for docking. 
Fig. 5. Trends in the binding 
energies,  Eb, of ligands 22–28 
to the DOR model optimized 
with ligand 15 –  and original 
receptor – . 
 
Fig. 6. The preferred conformations of ligands 22 and 26 in the 
DOR model optimized with compound 26. 
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CONCLUSIONS 
An automated docking procedure, combined with a short molecular dyna-
mics simulation, was applied in order to determine ligand specific receptor con-
formations for MOR and DOR receptors. It was established that one receptor 
conformation cannot reproduce correctly the binding of different ligands. Instead, 
a method is proposed to model a ligand specific receptor conformation for a se-
ries of ligands of similar size. The method consists of using an arbitrary model of 
an active receptor, manually docking a ligand representative of a series of ligands 
of similar size to the receptor, following the existing knowledge of key ligand–
receptor interactions; optimizing the receptor–ligand complex; allowing the re-
ceptor and the ligand to adjust their conformations in a short molecular dynamics 
run; extracting the most stable receptor–ligand complex structure and re-optimi-
zing its geometry. The receptor models obtained in this way were used for dock-
ing of different MOR and DOR ligands. They improved the resulting receptor 
ligand complexes both qualitatively (increased number of close interactions with 
amino acids important for binding, as found by point mutation studies) and quan-
titatively (improved correlation between the experimentally measured and calcu-
lated binding energies). 
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Рачунска метода аутоматизованог докирања примењена је на везивање серије лиганада, 
специфичних за μ- и δ-рецепторе, за моделе ових рецептора. Краткотрајна молекулско дина-
мичка симулација је коришћена за добијање конформација ових рецептора које су специ-
фичне за поједине лиганде, полазећи од случајно изабраног модела активираног рецептора. 
Квалитет овако добијеног модела рецептора зависи од молекулске запремине лиганда у ли-
ганд–рецептор комплексу коришћеног у молекулско-динамичкој симулацији. За серију ли-
ганда сличне запремине резултати докирања су у складу са експерименталним резлтатима 
мутација аминокиселина у рецептору. Корелација израчунатих и мерених енергија везивања 
је побољшана у односу на резултате добијене са полазном конформацијом рецептора. 
(Примљено 20. јануара 2011) 
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